Patents by Inventor Yifei Zhong

Yifei Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of preparing ATG's analogue, and the application of ATG and it's analogue
    Patent number: 9994533
    Abstract: The present invention provides the use of ATG in the preparation of a reagent for adjusting the activity of PP2A; and the use of ATG in increasing the activity of PP2A in 293T cells. The present invention also provides the use of the arctigenin in the preparation of the medicine for reducing the proteinuria of the diabetic mice. The present invention also provides the use of the arctigenin in the preparation of the reagent for inhibiting the expression of the NOX4 gene. The present invention also provides analogs of arctigenin and application thereof. The present invention provides a novel use of ATG for modulating PP2A activity, and ATG can also significantly reduce proteinuria in diabetic mice. At the same time, arctigenin could significantly inhibit the expression of NOX4 in STZ-eNOS?/? mice glomeruli. The ATG analogs of the present invention are more effective than the native ATG.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: June 12, 2018
    Assignee: Longhua Hospital Shanghai University of Traditional Chinese Medicine
    Inventors: Yifei Zhong, Honggang Gu
  • Method of preparing ATG's analogue, and the application of ATG and it's analogue
    Publication number: 20170313667
    Abstract: The present invention provides the use of ATG in the preparation of a reagent for adjusting the activity of PP2A; and the use of ATG in increasing the activity of PP2A in 293T cells. The present invention also provides the use of the arctigenin in the preparation of the medicine for reducing the proteinuria of the diabetic mice. The present invention also provides the use of the arctigenin in the preparation of the reagent for inhibiting the expression of the NOX4 gene. The present invention also provides analogues of arctigenin and application thereof. The present invention provides a novel use of ATG for modulating PP2A activity, and ATG can also significantly reduce proteinuria in diabetic mice. At the same time, arctigenin could significantly inhibit the expression of NOX4 in STZ-eNOS?/? mice glomeruli. The ATG analogues of the present invention are more effective than the native ATG.
    Type: Application
    Filed: March 17, 2017
    Publication date: November 2, 2017
    Applicant: Longhua Hospital Shanghai University of Traditional Chinese Medicine
    Inventors: Yifei Zhong, John Cijiang He, Bhaskar Das, Ruijie Liu, Honggang Gu